Literature DB >> 31131617

Prebiotic effect of two grams of lactulose in healthy Japanese women: a randomised, double-blind, placebo-controlled crossover trial.

Y Sakai1, N Seki1, K Hamano2, H Ochi1, F Abe1, K Masuda3, H Iino4.   

Abstract

Sixty healthy Japanese women with a defaecation frequency of 2-4 times/week participated in this randomised, double-blind crossover trial. Participants received 2 g/day lactulose for 2 weeks and placebo in a random order, separated by a washout period of 3 weeks. Eight participants were excluded who did not satisfy the conditions, and therefore data from 52 were analysed. The primary outcome was defaecation frequency and the secondary outcomes were the number of defaecation days, faecal consistency, faecal volume, and the number and percentage of Bifidobacterium in faeces. The defaecation frequency (times/week) was significantly higher during lactulose (4.28±0.23) than placebo (3.83±0.23) treatment (delta (Δ) 0.45 [95% confidence interval (CI) 0.10-0.80], P=0.013). The defaecation days (days/week) was significantly higher during lactulose (3.77±0.17) than placebo (3.47±0.17) treatment (Δ0.30 [95% CI 0.04-0.56], P=0.024). Faecal consistency using the Bristol Stool Scale (/defaecation) was significantly higher during lactulose (3.84±0.10) than placebo (3.68±0.10) treatment (Δ0.16 [95% CI 0.00-0.31], P=0.044). Faecal volume (/week) was significantly higher during lactulose (21.73±3.07) than placebo (17.65±3.07) treatment (Δ4.08 [95% CI 0.57-7.60], P=0.024). The number of Bifidobacterium in faeces (log colony forming units/g faeces) was significantly higher during lactulose (9.53±0.06) than placebo (9.16±0.06) treatment (Δ0.37 [95% CI 0.23-0.49], P<0.0001). The percentage of Bifidobacterium in faeces was also significantly higher during lactulose (25.3±1.4) than placebo (18.2±1.4) treatment (Δ7.1 [95% CI 2.9-11.4], P=0.0014). Finally, straining at defaecation (/defaecation) during lactulose (3.62±0.24) treatment was significantly lower than during placebo (3.97±0.24) treatment (Δ0.35 [95% CI -0.69 - -0.02], P=0.037). No significant difference was observed between lactulose and placebo with regard to flatulence. Severe adverse effects did not occur. Thus, oral ingestion of 2 g/day lactulose had a prebiotic effect, increasing the number and percentage of bifidobacteria in faeces, softening the faeces, and increasing defaecation frequency, but without increasing flatulence.

Entities:  

Keywords:  bowel movement; constipation; gut microbiome; indigestible oligosaccharide; intestinal regulation

Year:  2019        PMID: 31131617     DOI: 10.3920/BM2018.0174

Source DB:  PubMed          Journal:  Benef Microbes        ISSN: 1876-2883            Impact factor:   4.205


  5 in total

1.  2'-Fucosyllactose Increases the Abundance of Blautia in the Presence of Extracellular Fucosidase-Possessing Bacteria.

Authors:  Ayako Horigome; Nanami Hashikura; Keisuke Yoshida; Jin-Zhong Xiao; Toshitaka Odamaki
Journal:  Front Microbiol       Date:  2022-06-02       Impact factor: 6.064

2.  Bifidobacterium response to lactulose ingestion in the gut relies on a solute-binding protein-dependent ABC transporter.

Authors:  Keisuke Yoshida; Rika Hirano; Yohei Sakai; Moonhak Choi; Mikiyasu Sakanaka; Shin Kurihara; Hisakazu Iino; Jin-Zhong Xiao; Takane Katayama; Toshitaka Odamaki
Journal:  Commun Biol       Date:  2021-05-10

Review 3.  The potential role of lactulose pharmacotherapy in the treatment and prevention of diabetes.

Authors:  Natural Chu; James Ling; He Jie; Kathy Leung; Emily Poon
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-15       Impact factor: 6.055

4.  Prebiotic Food Intake May Improve Bone Resorption in Japanese Female Athletes: A Pilot Study.

Authors:  Tatsuya Ishizu; Eri Takai; Suguru Torii; Motoko Taguchi
Journal:  Sports (Basel)       Date:  2021-06-04

Review 5.  Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults.

Authors:  Michele Pier Luca Guarino; Annamaria Altomare; Sara Emerenziani; Claudia Di Rosa; Mentore Ribolsi; Paola Balestrieri; Paola Iovino; Giulia Rocchi; Michele Cicala
Journal:  Nutrients       Date:  2020-04-09       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.